
# SouthernBiotech <sup>†</sup>



# **Mouse Anti-Phosphotyrosine**

Cat. No.	Format	Size
1400-01	Purified (UNLB)	0.5 mg
1400-02	Fluorescein (FITC)	0.5 mg
1400-04	Alkaline Phosphatase (AP)	1.0 mL
1400-05	Horseradish Peroxidase (HRP)	1.0 mL
1400-08	Biotin (BIOT)	0.5 mg
1400-09	R-phycoerythrin (PE)	0.1 mg



FLISA plate was coated with BSA and BSA conjugated to phosphotyrosine (pTry-BSA). Phosphotyrosine was detected with serially diluted Mouse Anti-Phosphotyrosine-PE (SB Cat. No. 1400-09).

#### **Overview**

Clone PY20

**Isotype** Mouse (BALB/c)  $IgG_{2b}\kappa$ 

**Immunogen** Phosphotyrosine conjugated to carrier proteins

**Specificity** Tyrosine-phosphorylated proteins

Alternate Name(s) pTyr

# **Description**

Protein tyrosine residues are phosphorylated as a result of intracellular protein kinase activation (e.g., via growth factors) during normal growth and development and in oncogenesis. The most abundant population of target proteins for tyrosine phosphorylation is cell surface glycoproteins. Antibodies to phosphotyrosine enable the detection, isolation, and characterization of proteins containing phosphotyrosine. The monoclonal antibody PY20 prevents internalization of activated receptors (e.g., EGFR) when microinjected into cells. The affinity of PY20 for phosphotyrosine is approximately 10<sup>-6</sup> to 10<sup>-7</sup> M. PY20 binding to phosphorylated tyrosines can be inhibited by free phosphotyrosine and phenylphosphate but not by phosphoserine, phosphothreonine, or free phosphate.

### **Applications**

ELISA – Quality tested <sup>1-4</sup>
FLISA – Quality tested
WB – Reported in literature <sup>1,5-7</sup>
IP – Reported in literature <sup>5</sup>
IHC-PS – Reported in literature <sup>8</sup>
IHC-WM – Reported in literature <sup>9</sup>
ICC – Reported in literature <sup>10</sup>
FC – Reported in literature <sup>11</sup>
Microarray – Reported in literature <sup>12,13</sup>
Purification – Reported in literature <sup>1,14</sup>

#### **Working Dilutions**

ELISA	AP conjugate	1:1,000 - 1:2,000
	HRP conjugate	1:1,000 - 1:4,000
	BIOT conjugate	1:5,000 - 1:10,000
FLISA	FITC conjugate	1:200 – 1:400
	PE conjugate	≤ 1 μg/mL
Other Applications	Since applications vary, you should determine the optimum working dilution for the product that is appropriate for your specific need.	

For Research Use Only. Not for Diagnostic or Therapeutic Use.

Email: info@southernbiotech.com • Website: www.southernbiotech.com

# **Handling and Storage**

- The purified (UNLB) antibody is supplied as 0.5 mg of purified immunoglobulin in 1.0 mL of borate buffered saline, pH 8.2. No
  preservatives or amine-containing buffer salts added. Store at 2-8°C.
- The fluorescein (FITC) conjugate is supplied as 0.5 mg in 1.0 mL of PBS/NaN<sub>3</sub>. Store at 2-8°C.
- The alkaline phosphatase (AP) conjugate is supplied as 1.0 mL in a stock solution of 50 mM Tris/1 mM MgCl₂/50% glycerol, pH 8.0, containing NaN₃ as preservative. Store at 2-8°C or long-term at -20°C.
- The horseradish peroxidase (HRP) conjugate is supplied as 1.0 mL in a stock solution of 50% glycerol/50% PBS, pH 7.4. No preservative added. Store at 2-8°C or long-term at -20°C.
- The biotin (BIOT) conjugate is supplied as 0.5 mg in 1.0 mL of PBS/NaN<sub>3</sub>. Store at 2-8°C.
- The R-phycoerythrin (PE) conjugate is supplied as 0.1 mg in 1.0 mL of PBS/NaN<sub>3</sub> and a stabilizing agent. Store at 2-8°C. Do not freeze!
- Protect fluorochrome-conjugated forms from light. Reagents are stable for the period shown on the label if stored as directed.

#### Warning

Some reagents contain sodium azide. Please refer to product specific SDS.

#### References

- Glenney JR Jr, Zokas L, Kamps MP. Monoclonal antibodies to phosphotyrosine. J Immunol Methods. 1988;109:277-85. (Immunogen, ELISA, WB, Purification)
- 2. Ruff-Jamison S, Campos-González R, Glenney JR Jr. Heavy and light chain variable region sequences and antibody properties of antiphosphotyrosine antibodies reveal both common and distinct features. J Biol Chem. 1991;266:6607-13. (ELISA)
- 3. Lietha D, Eck MJ. Crystal structures of the FAK kinase in complex with TAE226 and related bis-anilino pyrimidine inhibitors reveal a helical DFG conformation. PLoS One. 2008;3(11):e3800. (ELISA)
- 4. Antila H, Autio H, Turunen L, Harju K, Tammela P, Wennerberg K, et al. Utilization of in situ ELISA method for examining Trk receptor phosphorylation in cultured cells. J Neurosci Methods. 2014;222:142-6. (ELISA)
- 5. Vouri K, Ruoslahti E. Tyrosine phosphorylation of p130<sup>Cas</sup> and cortactin accompanies integrin-mediated cell adhesion to extracellular matrix. J Biol Chem. 1995;270:22259-62. (WB, IP)
- 6. Elliott S, Egrie J, Browne J, Lorenzini T, Busse L, Rogers N, et al. Control of rHuEPO biological activity: the role of carbohydrate. Exp Hematol. 2004;32:1146-55. (WB)
- 7. Wang X, Cahill ME, Werner CT, Christoffel DJ, Golden SA, Xie Z, et al. Kalirin-7 mediates cocaine-induced AMPA receptor and spine plasticity, enabling incentive sensitization. J Neurosci. 2013;33:11012-22. (WB)
- 8. Haralambieva E, Jones M, Roncador GM, Cerroni L, Lamant L, Ott G, et al. Tyrosine phosphorylation in human lymphomas. Histochem J. 2002;34:545-52. (IHC-PS)
- 9. Gorczyca M, Augart C, Budnik V. Insulin-like receptor and insulin-like peptide are localized at neuromuscular junctions in Drosophila. J Neurosci. 1993;13:3692-704. (IHC-WM)
- 10. Takagi S, Daibata M, Last TJ, Humphreys RE, Parker DC, Sairenji T. Intracellular localization of tyrosine kinase substrates beneath crosslinked surface immunoglobulins in B cells. J Exp Med. 1991;174:381-8. (ICC)
- 11. Lund-Johansen F, Davis K, Bishop J, de Waal Malefyt R. Flow cytometric analysis of immunoprecipitates: high-throughput analysis of protein phosphorylation and protein-protein interactions. Cytometry. 2000;39:250-9. (FC)
- 12. Sikkema AH, de Bont ES, Molema G, Dimberg A, Zwiers PJ, Diks SH, et al. Vascular endothelial growth factor receptor 2 (VEGFR-2) signalling activity in paediatric pilocytic astrocytoma is restricted to tumour endothelial cells. Neuropathol Appl Neurobiol. 2011;37:538-48. (Microarray)
- 13. Rosenberger AF, Hilhorst R, Coart E, García Barrado L, Naji F, Rozemuller AJ, et al. Protein kinase activity decreases with higher braak stages of alzheimer's disease pathology. J Alzheimers Dis. 2016;49:927-43. (Microarray)
- 14. Glenney JR Jr, Zokas L. Novel tyrosine kinase substrates from Rous sarcoma virus-transformed cells are present in the membrane skeleton. J Cell Biol. 1989;108:2401-8. (Purification)

TB1400 16-Jul-18

Email: info@southernbiotech.com • Website: www.southernbiotech.com